Varun Daga partner at a unicorn company: Invested in a micro-cap stock with huge reserves and promising dividend yield!
Varun Daga's substantial stake in the company, standing at a remarkable 11.50 per cent
The stock market, a captivating stage of economic intricacies, unveils the perpetual dance of supply and demand that dictates prices. It is a dynamic and vibrant display, where the values of listed companies are continuously scrutinized, uncovering hidden gems or vulnerabilities. These price dynamics, a reflection of marketplace behavior, can lead traders to remarkable gains or catastrophic losses, while investors find opportunities for satisfying and steady returns.
What makes the stock market truly fascinating is its accessibility to those willing to delve into its intricacies. Mastery of the art of investing opens the door to an enjoyable and exhilarating wealth-building journey, paving the way for financial security, retirement comfort, and the creation of a lasting legacy through substantial lifetime returns.
Today, our spotlight turns to Varun Daga, a figure who operates behind the curtain yet holds significant influence. The founder of Girik Advisors LLP, Mr. Daga serves as the Director and Manager-Investment Fund at Girik Advisors LLP and holds positions on the boards of various other companies. Notably, he is also the designated partner of Dream 11 Gaming Zone LLP, a unicorn company.
Enter Denis Chem Lab Ltd (DCLL), a company with a rich history dating back to July 1980. Originally incorporated as Denis Chem Lab Pvt Ltd (DCLPL) by Mr. Himanshu C Patel and his family, it transformed into a public limited company in April 1982, rebranded as DCLL. The company specializes in manufacturing IVF bottles under three packaging categories: glass bottles, Euroheads, and plastic bottles utilizing blow-fill-seal technology. Their WHO GMP-certified manufacturing facility in Gandhinagar boasts an impressive installed capacity, producing a range of sterile Intravenous injectables in volumes from 100 ml to 10 liters.
DCLL's product profile includes antibiotic injections, diuretic injections, parenteral amino acid injections, plasma volume expanders, anti-anaerobic injections, anti-pyretic Inj., irrigation solutions, and dialysis solutions, among others. As a micro-cap company with a market cap of Rs 171 crore and a dividend yield of 1.58 per cent, DCLL reported its highest-ever sales in the quarter ending September 2023. With an equity capital of approximately Rs 14 crore and reserves of Rs 61 crore, this company is positioned in the market with an enticing market cap of just Rs 171 crore.
What adds an intriguing dimension to this narrative is Varun Daga's substantial stake in the company, standing at a remarkable 11.50 per cent. The stock has exhibited an impressive performance, delivering a return of 41.56 per cent in the last year.